- Home
- HOWL vs APLT Comparison
HOWL vs APLT Comparison
Compare HOWL & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HOWL | APLT |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | 28 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 64.5M | 18.0M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | HOWL | APLT |
|---|---|---|
| Price | $0.69 | $0.13 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 6 | 3 |
| Target Price | ★ $6.50 | $1.25 |
| AVG Volume (30 Days) | 796.4K | ★ 8.6M |
| Earning Date | 11-04-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | $124.18 |
| Revenue Next Year | N/A | $66.67 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $0.10 |
| 52 Week High | $2.38 | $1.50 |
Technical Indicators
Market Signals| Indicator | HOWL | APLT |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 27.06 |
| Support Level | $0.56 | $0.10 |
| Resistance Level | $1.20 | $0.13 |
| Average True Range (ATR) | 0.10 | 0.02 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 19.49 | 17.28 |
Price Performance
Historical ComparisonAbout HOWL Werewolf Therapeutics Inc.
Werewolf Therapeutics Inc is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It is leveraging its proprietary PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment or TME.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.